tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Dec 7;ciac933.
doi: 10.1093/cid/ciac933. Online ahead of print.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae[SUP] 1 [/SUP], Hiroshi Yotsuyanagi[SUP] 2 [/SUP], Norio Ohmagari[SUP] 3 [/SUP], Yohei Doi[SUP] 4 5 [/SUP], Hiroki Sakaguchi[SUP] 6 [/SUP], Takuhiro Sonoyama[SUP] 6 [/SUP], Genki Ichihashi[SUP] 6 [/SUP], Takao Sanaki[SUP] 7 [/SUP], Keiko Baba[SUP] 7 [/SUP], Yuko Tsuge[SUP] 6 [/SUP], Takeki Uehara[SUP] 6 [/SUP]
Affiliations
Abstract
Background: This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic.
Methods: Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on day 1) or 250 mg (750 mg on day 1) or placebo once daily for 5 days. The co-primary endpoints were the change from baseline in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer on day 4 and time-weighted average change from baseline up to 120 hours in the total score of predefined 12 COVID-19 symptoms. Safety was assessed through adverse events.
Results: A total of 341 patients (ensitrelvir 125 mg group, 114; ensitrelvir 250 mg group, 116; and placebo group, 111; male, 53.5%-64.9%; mean age, 35.3-37.3 years) were included in the efficacy analyses. The change from baseline in the SARS-CoV-2 titer on day 4 was significantly greater with both ensitrelvir doses than with placebo (differences from placebo: -0.41 log10 50% tissue-culture infectious dose/mL, P < 0.0001 for both). The total score of the 12 COVID-19 symptoms did not show a significant difference between the ensitrelvir groups and placebo group. The time-weighted average change from baseline up to 120 hours was significantly greater with ensitrelvir versus placebo in several subtotal scores, including acute symptoms and respiratory symptoms. Most adverse events were mild in severity.
Conclusions: Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile.
Keywords: COVID-19; S-217622; SARS-CoV-2 3C-like protease inhibitor; ensitrelvir; viral titer.
. 2022 Dec 7;ciac933.
doi: 10.1093/cid/ciac933. Online ahead of print.
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Hiroshi Mukae[SUP] 1 [/SUP], Hiroshi Yotsuyanagi[SUP] 2 [/SUP], Norio Ohmagari[SUP] 3 [/SUP], Yohei Doi[SUP] 4 5 [/SUP], Hiroki Sakaguchi[SUP] 6 [/SUP], Takuhiro Sonoyama[SUP] 6 [/SUP], Genki Ichihashi[SUP] 6 [/SUP], Takao Sanaki[SUP] 7 [/SUP], Keiko Baba[SUP] 7 [/SUP], Yuko Tsuge[SUP] 6 [/SUP], Takeki Uehara[SUP] 6 [/SUP]
Affiliations
- PMID: 36477182
- DOI: 10.1093/cid/ciac933
Abstract
Background: This phase 2b part of a randomized phase 2/3 study assessed the efficacy and safety of ensitrelvir for mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron epidemic.
Methods: Patients were randomized (1:1:1) to orally receive ensitrelvir fumaric acid 125 mg (375 mg on day 1) or 250 mg (750 mg on day 1) or placebo once daily for 5 days. The co-primary endpoints were the change from baseline in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) titer on day 4 and time-weighted average change from baseline up to 120 hours in the total score of predefined 12 COVID-19 symptoms. Safety was assessed through adverse events.
Results: A total of 341 patients (ensitrelvir 125 mg group, 114; ensitrelvir 250 mg group, 116; and placebo group, 111; male, 53.5%-64.9%; mean age, 35.3-37.3 years) were included in the efficacy analyses. The change from baseline in the SARS-CoV-2 titer on day 4 was significantly greater with both ensitrelvir doses than with placebo (differences from placebo: -0.41 log10 50% tissue-culture infectious dose/mL, P < 0.0001 for both). The total score of the 12 COVID-19 symptoms did not show a significant difference between the ensitrelvir groups and placebo group. The time-weighted average change from baseline up to 120 hours was significantly greater with ensitrelvir versus placebo in several subtotal scores, including acute symptoms and respiratory symptoms. Most adverse events were mild in severity.
Conclusions: Ensitrelvir treatment demonstrated a favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile.
Keywords: COVID-19; S-217622; SARS-CoV-2 3C-like protease inhibitor; ensitrelvir; viral titer.